Search
Search
Szilard Kiss, MD
Show Description +
Szilárd Kiss, MD, discusses results from a phase 2 multicenter trial that compared encapsulated cell technology (ECT; NT-503-3) with aflibercept (Eylea, Regeneron) in patients who were not treatment-naïve. According to Dr. Kiss, the implanted cells did not work as well as they did in the preclinical animal trials. The phase 2 trial was terminated early due to the number of rescue injections needed. For patients with wet AMD, there is still hope that this technology may prove to be a long-term delivery mechanism for patients who need repeated intravitreal injections.
Posted: 8/03/2016
Szilard Kiss, MD
Szilárd Kiss, MD, discusses results from a phase 2 multicenter trial that compared encapsulated cell technology (ECT; NT-503-3) with aflibercept (Eylea, Regeneron) in patients who were not treatment-naïve. According to Dr. Kiss, the implanted cells did not work as well as they did in the preclinical animal trials. The phase 2 trial was terminated early due to the number of rescue injections needed. For patients with wet AMD, there is still hope that this technology may prove to be a long-term delivery mechanism for patients who need repeated intravitreal injections.
Posted: 8/03/2016
Bryn Mawr Communications, LLC, and Eyetube.net are not affiliated with the official program of ASRS: 2016.
Please log in to leave a comment.